Asefarma Competitors

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM).

Zambon is a chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients' lives better. Present in Europe, America and Asia with over 2,700 employees and manufacturing units in Italy, Switzerland, France, China and Brazil, in 2024 the Group revenues amounted to 885 million euros. Zambon SpA, the pharma subsidiary of the group with its 23 branchess and products commercialized in 87 countries, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. In recent years the Group established ZBiotech, a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules. Zambon also produces high quality products thanks to the management of the whole production chain which involves Zach-Zambon Chemicals, a privileged partner for API, custom synthesis and generic products. Zambon complements the offering of medicines with modern health solutions. Through Zcube-Zambon Research Venture it actively scouts and supports the growth of innovative projects and startups. The Zambon group also includes ItaliAssistenza, a Home Care Company involved in the design and delivery of patient support programs (PSP) and home care services. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.